What Role Does the Hydrochloride Salt Serve in C-Terminal Protection During Solution-Phase Peptide Assembly?

In cGMP solution-phase peptide trains, L-alanine ethyl ester hydrochloride is not charged as the free amine; it is first neutralized in situ with a tertiary amine such as N,N-diisopropylethylamine or triethylamine to liberate the free ethyl ester, after which the ester acts as a C-terminal protected nucleophile in carbodiimide-mediated or aminium-mediated couplings. Qualification for this use is governed by ICH Q7 Section 7.3 for receiving, quarantine, and release of raw materials, with residual solvent limits aligned to ICH Q3C class 2 and class 3 thresholds and elemental impurity limits per USP 232 and USP 233; the hydrochloride salt is typically released with loss on drying ≤0.5% w/w, chloride content 98.0–102.0% of theoretical, and single unspecified impurity ≤0.10% by HPLC area. Documented route descriptions charge the hydrochloride salt at 1.0–1.2 mol per 1.0 mol of N-protected amino acid or acyl donor after adjustment for freebase liberation, with coupling reagents selected from 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide/hydroxybenzotriazole or HATU/DIPEA combinations in anhydrous dichloromethane, tetrahydrofuran, or acetonitrile at 0–5°C for the initial 30–60 min of activation. Where ambient relative humidity exceeds 60%, the salt is pre-dried under vacuum at 40°C for 4 h before charging. Process-scale equipment for this operation includes glass-lined reactors with bottom discharge valves configured for aqueous workup, and in several published route descriptions the crude ethyl ester peptide is carried forward without isolation into saponification using 1.0–1.2 equivalents of lithium hydroxide in tetrahydrofuran-water at 0–10°C. The downstream terminal products are alanine-containing peptide fragments, protected dipeptide and tripeptide intermediates, and final peptide APIs after deprotection and lyophilization; residual solvent levels in the isolated peptide are typically controlled to ≤500 ppm for ethyl acetate and ≤600 ppm for acetonitrile according to ICH Q3C.

N-Carboxyanhydride Feedstock Conversion in Poly(amino acid) Production

Poly(L-alanine) segments and alanine-containing copolypeptides are derived through ring-opening polymerization of L-alanine N-carboxyanhydride prepared from the ethyl ester hydrochloride. In this route, the salt is suspended in anhydrous tetrahydrofuran and treated with 1.05–1.20 equivalents of a tertiary amine at −5 to 0°C; the liberated ester is then added to a phosgene or triphosgene solution under a dry-nitrogen sweep to form the N-carboxyanhydride via cyclization. Published laboratory protocols indicate a use ratio of 1.0 mol amino acid ester to 0.34–0.40 mol triphosgene for NCA formation, although production-scale batches may adjust within that range based on phosgene equivalent availability; triphosgene handling and off-gas treatment follow local chemical safety regulations and require phosgene scrubbers with continuous pH monitoring. Process-control limits are narrow: reactor jacket temperature for cyclization is held at ±5°C of the set point, and headspace moisture is maintained below 50 ppm because hydrolysis byproducts from free acid formation alter NCA monomer crystallinity and broaden the molecular weight distribution. Compliance for biomedical polymer outputs references ISO 13485:2016 for medical device quality systems and ISO 10993-1:2018 for biological evaluation when the final poly(amino acid) is used in implantable hydrogels or drug delivery depots; residual tin, chloride, and solvent limits are controlled according to ICH Q3D and ICH Q3C when the polymer enters a drug formulation. After NCA precipitation from n-heptane, ring-opening polymerization is initiated with hexylamine or amino-terminated poly(ethylene glycol) at a monomer-to-initiator ratio between 20:1 and 200:1 in anhydrous N,N-dimethylformamide at 25°C, with monomer conversion monitored by Fourier-transform infrared disappearance of the anhydride carbonyl band at 1858 cm⁻¹ and 1786 cm⁻¹. Terminal products are poly(alanine)-based nanoparticles, peptide-hydrogel matrices, and copolymer drug carriers; terminal alkylamine initiators are removed by dialysis or precipitation when the product enters parenteral use.

In quality-control laboratories supporting amino acid derivative manufacture, L-alanine ethyl ester hydrochloride is converted into single-enantiomer calibration standards and system-suitability markers rather than used directly as a derivatizing reagent. The ester is first treated with methanolic ammonia or ammonium carbonate to yield L-alaninamide, which is then chromatographed against the D-isomer by high-performance liquid chromatography on a chiral stationary phase such as cellulose tris(4-methylbenzoate)-coated silica; the mobile phase consists of 0.1% trifluoroacetic acid in water and acetonitrile at a flow rate of 1.0 mL/min. Working standard solutions for method linearity are prepared at 0.05–1.0 mg/mL in 50:50 acetonitrile-water, with acceptance criteria for area repeatability set at relative standard deviation ≤2.0% across six injections per USP 621 chromatographic practices. Compliance for this application falls under ISO/IEC 17025:2017 for laboratory competence and ISO 17034:2016 for reference material producers when the derived standard is shipped with a certificate of analysis; the ester precursor itself is required to have enantiomeric excess ≥99.0% and related substances ≤0.5% by area. In a typical batch, 10.0 g of the hydrochloride salt is neutralized with 1.05 equivalents of sodium bicarbonate in methanol-water at 20–25°C, the free ester is extracted into dichloromethane, and the organic phase is dried over sodium sulfate before ammonia treatment; the resulting alaninamide is recrystallized from ethanol-heptane and dried under vacuum at 40°C for 12 h. Terminal products are analytical reference materials, system suitability standards, and retained-sample qualification kits used in pharmaceutical release testing; shipped vials are labelled with expiration dates established by accelerated stability at 40°C and 75% relative humidity.

When the C-Terminal Alanine Residue of an ACE Inhibitor Requires Enantiopure Coupling Without Epimerization

Several published routes to alanine-containing angiotensin-converting enzyme inhibitors use the ethyl ester hydrochloride as the chiral alanine donor because the carboxyl is already protected and the α-carbon configuration can be retained during mixed anhydride or active ester couplings. The most sensitive process window is epimerization at the alanine α-carbon during activation with isobutyl chloroformate in the presence of N-methylmorpholine; reaction temperature is held between −25°C and −15°C, and the activated mixed anhydride is aged for 10–20 min before addition of the amine coupling partner. A typical charge ratio for this transformation is 1.0–1.3 equivalents of the hydrochloride salt per 1.0 equivalent of the carboxylic acid fragment after neutralization, with the tertiary amine base added at 1.0–1.05 equivalents relative to the hydrochloride to avoid excess amine-promoted racemization. Downstream hydrolysis of the ethyl ester to the free acid is performed with 1.05–1.15 equivalents of lithium hydroxide in 2:1 tetrahydrofuran-water at 0–5°C; the free acid is thereafter converted to the final salt form, such as perindopril erbumine or perindopril arginine, by salt exchange and crystallization in acetone-water. Compliance controls for intermediates destined for antihypertensive API synthesis follow ICH Q11 for starting material designation and impurity control, 21 CFR 211.110 for in-process sampling, and ICH Q3D for palladium or other metal residues when prior hydrogenation steps are involved. Terminal products include alanine-containing ACE inhibitor APIs, their crystalline salt forms, and registered intermediates in which the release specification includes enantiomeric excess ≥99.5%, individual unspecified impurity ≤0.10%, and residual ethyl acetate ≤500 ppm.

During synthesis of alanine-derived oxazoline ligands and Schiff base catalysts, the hydrochloride salt is neutralized with potassium carbonate in acetonitrile at 20–25°C and condensed with 1.0–1.05 equivalents of a substituted benzaldehyde in refluxing ethanol under Dean-Stark conditions; the addition ratio for the resulting Schiff base to metal precursor is typically 1:1 for Cu(II) or Zn(II) acetate, but documented ligand-to-metal screening ranges extend from 1:0.8 to 1:1.2 to optimize enantioselectivity in batch asymmetric additions. The downstream process is a two-stage operation: the Schiff base is isolated by crystallization from ethyl acetate-hexane, then complexation is carried out in methanol or dichloromethane under inert atmosphere at 40–60°C for 2–6 h, followed by filtration and vacuum drying at 50°C for 12 h. This application is governed by ISO 9001:2015 for fine chemical quality management and, when the ligand is exported into pharmaceutical synthesis, by ICH Q11 for materials of appropriate purity; no specific pharmacopoeial monograph covers all alanine-derived oxazoline ligands, so certificates of analysis rely on in-house HPLC methods with UV detection at 254 nm and chiral purity by polysaccharide-based columns. Published data for certain ligand-to-metal ratios are limited to bench-scale screening rather than production-scale runs; scale-up batches therefore require design-of-experiment verification of enantioselectivity and chemoselectivity before campaign approval. Terminal products are chiral oxazoline ligands, salen-type catalysts, and immobilized asymmetric catalyst precursors used in fine chemical and pharma synthesis.

Evaluating Residual Chloride and Solvent Carryover Limits When the Ester Is Consumed in Cosmetic Peptide Intermediates

Cosmetic peptide contract manufacturing consumes L-alanine ethyl ester hydrochloride as an upstream solution-phase coupling intermediate for short alanine-containing peptide sequences, but the chloride counterion is not carried into the finished cosmetic active. After the final coupling step, the peptide ethyl ester is saponified or subjected to preparative HPLC using 0.1% trifluoroacetic acid or acetic acid modifiers, and the peptide is isolated as the acetate or trifluoroacetate salt; residual free alanine ethyl ester is controlled to ≤0.10% w/w in the peptide dry matter. Coupling ratios used in this segment mirror solution-phase peptide practice: 1.0–1.1 equivalents of the hydrochloride salt per 1.0 equivalent of acyl donor are charged after neutralization with N,N-diisopropylethylamine in acetonitrile at 0–5°C, with activation by HATU or EDCI/HOBt. Compliance follows ISO 22716:2007 for cosmetic good manufacturing practices and EU Regulation (EC) No 1223/2009 where the resulting peptide is used in European Union formulations; residual solvent and chloride limits are aligned with ICH Q3C despite the cosmetic end use, because the contract manufacturer supplies multi-market cosmetic peptide grades. Terminal products are short-chain cosmetic peptides used in skin care formulations, including acetylated and palmitoylated alanine-containing peptides, supplied as lyophilized powders with peptide content ≥95.0% and chloride ≤100 ppm; the isolated peptide is typically stored at −20°C under argon to prevent aggregation and hydrolysis.